Karen Honey, PhD

As senior managing editor, science communications, Karen Honey, PhD, helps the AACR communicate scientific information to the public and educate the public about the importance of lifesaving cancer research. Before joining the AACR, Honey spent eight years working as an editor for two peer-reviewed scientific journals, first Nature Reviews Immunology and then The Journal of Clinical Investigation. During this time, she focused on communicating scientific discoveries to readers with all levels of knowledge, from the lay reader to the scientific expert. Before entering the world of science communication, Honey was a postdoctoral fellow in the laboratory of world-renowned immunologist Alexander Rudensky. She was born in the United Kingdom and received her doctorate in transplantation immunology from the University of Oxford. Honey currently lives in the Philadelphia suburbs.

FDA Approves New Lung Cancer Treatment and First Next-Gen Companion Diagnostic

Hot on the heels of the FDA’s landmark approval of an anticancer therapeutic for use based on whether a patient has a tumor with certain biomarkers, rather than a tumor originating at a certain anatomic site, the agency approved the first companion diagnostic that can detect mutations in multiple genes in a single test.

Read More

FDA Approves First Use for an Anticancer Therapeutic Based on Tumor Biomarker, Not Tumor Origin

Tuesday marked a milestone for the oncology community: The U.S. Food and Drug Administration (FDA) announced its first approval of an anticancer therapeutic for use based on whether a patient has a tumor with certain biomarkers and not where in the body the tumor originated.

Read More

FDA Approves Fourth Immune Checkpoint Inhibitor for Bladder Cancer

This time last year there were no immune checkpoint inhibitors approved by the U.S. Food and Drug Administration (FDA) for treating the most common form of bladder cancer—urothelial carcinoma. The approval of avelumab (Bavencio) earlier this week means there are now four of these revolutionary immunotherapeutics in the armamentarium.

Read More

FDA Approves Fourth ALK Inhibitor for Lung Cancer

Last week, a flurry of U.S. Food and Drug Administration (FDA) oncology approvals concluded with the approval of the molecularly targeted therapeutic brigatinib (Alunbrig) for treating certain patients with metastatic non–small cell lung cancer (NSCLC).

Read More

New Immune Checkpoint Inhibitor Approved for Bladder Cancer

Earlier this week, the U.S. Food and Drug Administration (FDA) announced that it had approved a new immune checkpoint inhibitor, durvalumab (Imfinzi), for the treatment of certain patients with the most common form of bladder cancer—urothelial carcinoma.

Read More

AACR Annual Meeting 2017: Most Merkel Cell Carcinoma Responses to the Newly FDA-Approved Avelumab Expected to Last More than a Year

T cells and antibodies

On March 23, the U.S. Food and Drug Administration announced the first-ever approval of a treatment for patients with a rare, aggressive form of skin cancer called Merkel cell carcinoma. The treatment, the immunotherapeutic avelumab (Bavencio), was approved based on data from the JAVELIN Merkel 200 phase II clinical trial.

Read More